Pharmaceuticals, Biotechnology and Life Sciences
Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease Pfizer acquires 15% ownership stake in…
Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.
Basilea Pharmaceutica cahsed $5 million from Pfizer’s milestone payment triggered for selling of the antifungal Cresemba in Europe..
BioMarin Pharmaceutical has received $20 million in milestone payments from Pfizer Inc, it said Thursday.
The U.S. Food and Drug Administration today expanded the approval of Pfizer’s Xeljanz (tofacitinib), the first oral medication approved for…
Pfizer has appointed a professor of molecular immunology Dr. Dan R. Littman to its Board of Directors, was also appointed…
ViiV Healthcare on Thursday said it has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United…
Basilea Pharmaceutica and Pfizer have extended their license agreement for Basilea’s antifungal Cresemba to China and sixteen countries in Asia…
Basilea Pharmaceutica International has amended its existing license agreement for Europe, Russia, Turkey and Israel with Pfizer Inc. for Basilea’s…
Basilea Pharmaceutica said Thursday its licensing partner Pfizer recently launched the antifungal drug Cresemba (isavuconazole) in Spain. Pfizer is now commercializing…